The FDA stated in a press release regarding its refusal of a marketing application that Juul Labs' tobacco products lacked sufficient evidence regarding their toxicological characteristics before being introduced to the market. Additionally, due to insufficient and conflicting data, some research results have raised concerns.
Juul Labs believes that every flaw in the marketing restrictions is based on an incorrect and incomplete evaluation of the data. If the data is properly evaluated in the pre-market applications, FDA can accurately assess the toxicological characteristics of Juul products relative to other tobacco products, including combustible cigarettes. The appeal also states that all perceived limitations can be resolved through clarification by FDA in the usual iterative process followed for previous applications.
Juul Labs has filed an appeal at an approximate value of 10.75, requesting the overturning of the marketing refusal order and reinstatement of its pre-market tobacco product application for substantive review by the FDA. This would allow for a comprehensive and fair assessment of Juul's system to determine whether it is suitable for protecting public health. In a press release, Juul stated that they believe their marketing authorization should be granted once all scientific evidence presented in the application is reviewed comprehensively by the FDA - in accordance with legal requirements and without political interference.
Background: In July 2020, Juul Labs submitted a premarket tobacco product application to the FDA for its currently marketed products and new devices with age verification technology. The application includes over 125,000 pages of data, information, and analysis from more than 110 scientific studies covering non-clinical (over 75 studies), clinical (14 studies), and behavioral (21 studies) research plans to support Juul's product marketing. The company also evaluated the correlation between its products and combustible cigarettes, FDA-authorized heated tobacco products (IQOS), and other vapor products on the market.
Despite the scientific evidence, on June 23, 2022, the FDA issued a marketing denial order for Juul Labs' tobacco products prior to their release. On July 5, the FDA maintained the marketing denial order and announced it will review the decision after determining "unique scientific questions requiring further review" exist with the application.
Statement:
This article is compiled from third-party information and is only intended for industry exchange and learning.
This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the authenticity and accuracy of its content. The translation of this article is solely intended for communication and research within the industry.
Due to limitations in our translation abilities, the translated article may not fully convey the exact meaning of the original text. Please refer to the original article for accuracy.
2FIRSTS is fully aligned with the stance of the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or foreign-related issues and statements.
The copyright for the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
